{"id":"tc-chemotherapy","safety":{"commonSideEffects":[{"rate":"60–80","effect":"Neutropenia"},{"rate":"40–60","effect":"Anemia"},{"rate":"20–40","effect":"Thrombocytopenia"},{"rate":"30–50","effect":"Nausea and vomiting"},{"rate":"50–70","effect":"Alopecia"},{"rate":"10–20","effect":"Peripheral neuropathy"},{"rate":"40–60","effect":"Fatigue"},{"rate":"10–30","effect":"Mucositis"}]},"_chembl":{"chemblId":"CHEMBL1738872","moleculeType":"Small molecule","molecularWeight":"439.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Docetaxel is a taxane that stabilizes microtubules and prevents their disassembly, leading to cell cycle arrest and apoptosis. Cyclophosphamide is an alkylating agent that cross-links DNA strands, preventing replication and transcription. Together, TC exploits complementary mechanisms to enhance cytotoxic effects against cancer cells.","oneSentence":"TC chemotherapy is a combination regimen of docetaxel (Taxotere) and cyclophosphamide that disrupts microtubule dynamics and cross-links DNA to kill rapidly dividing cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:11:16.973Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (adjuvant and neoadjuvant treatment)"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT07284121","phase":"","title":"A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-07-17","conditions":"Lung Cancer, Hepatocellular Carcinoma","enrollment":700},{"nctId":"NCT04432207","phase":"PHASE1","title":"A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Imugene Limited","startDate":"2020-11-30","conditions":"Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV","enrollment":24},{"nctId":"NCT07457541","phase":"PHASE1","title":"Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tomsk National Research Medical Center of the Russian Academy of Sciences","startDate":"2026-02-26","conditions":"Lung Cancer (Locally Advanced or Metastatic), Pancreas Cancer, Metastatic, Breast Cancer (Locally Advanced or Metastatic)","enrollment":15},{"nctId":"NCT02324387","phase":"NA","title":"Tc99m Sestamibi Molecular Breast Imaging","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06-15","conditions":"Breast Cancer","enrollment":96},{"nctId":"NCT07432178","phase":"PHASE3","title":"CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-02-23","conditions":"Breast Cancer","enrollment":2288},{"nctId":"NCT07102940","phase":"PHASE2","title":"Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"George Washington University","startDate":"2026-05-01","conditions":"Breast Cancer, HER 2 Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer","enrollment":50},{"nctId":"NCT07423611","phase":"PHASE2","title":"ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-10-01","conditions":"Breast Cancer","enrollment":388},{"nctId":"NCT07242417","phase":"EARLY_PHASE1","title":"TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2025-12-18","conditions":"Solid Cancer, GPC3 Positive Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT07306663","phase":"PHASE3","title":"Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2021-06-01","conditions":"Esophageal Cancer","enrollment":242},{"nctId":"NCT05256745","phase":"PHASE1, PHASE2","title":"RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer","status":"RECRUITING","sponsor":"Georgetown University","startDate":"2023-06-06","conditions":"Cancer Related Cognitive Decline, Non-metastatic Breast Cancer","enrollment":48},{"nctId":"NCT07271602","phase":"PHASE2","title":"A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-01-30","conditions":"Non Small Cell Lung Cancer, Immunotherapy, Radiotherapy","enrollment":104},{"nctId":"NCT06007586","phase":"PHASE3","title":"Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients","status":"COMPLETED","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2024-05-31","conditions":"Gynecological Tumor, Ovarian Cancer, Cervical Cancer","enrollment":143},{"nctId":"NCT07246304","phase":"EARLY_PHASE1","title":"TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC","status":"RECRUITING","sponsor":"TCRCure Biopharma Ltd.","startDate":"2025-11-30","conditions":"Small Cell Lung Cancer ( SCLC ), CAR-T Cell Therapy","enrollment":24},{"nctId":"NCT02744053","phase":"EARLY_PHASE1","title":"DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-11-07","conditions":"Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative","enrollment":96},{"nctId":"NCT07212933","phase":"PHASE2","title":"The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-07-01","conditions":"Gastric (Stomach) Cancer, Biological Therapy, Immunotherapy","enrollment":90},{"nctId":"NCT07205497","phase":"PHASE2","title":"QL1706 Plus Neoadjuvant Chemotherapy Followed by Type I Hysterectomy for Locally Advanced Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-03-28","conditions":"Neoadjuvant Immunotherapy, Locally Advanced Cervical Cancer","enrollment":54},{"nctId":"NCT04105270","phase":"PHASE2","title":"RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2022-11-30","conditions":"Adenocarcinoma of Lung, Lung Cancer","enrollment":82},{"nctId":"NCT06509568","phase":"PHASE2","title":"Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-08-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":92},{"nctId":"NCT04047862","phase":"PHASE1","title":"Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-08-15","conditions":"Locally Advanced and Metastatic Solid Tumors","enrollment":446},{"nctId":"NCT07121595","phase":"PHASE2","title":"Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2025-07-17","conditions":"Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8","enrollment":50},{"nctId":"NCT07112833","phase":"PHASE2","title":"A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-08-10","conditions":"Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma","enrollment":36},{"nctId":"NCT06027541","phase":"","title":"Young Patients With Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-08-01","conditions":"Breast Cancer Female","enrollment":1000},{"nctId":"NCT01564056","phase":"PHASE3","title":"Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2012-04-12","conditions":"Breast Cancer","enrollment":1989},{"nctId":"NCT07005557","phase":"PHASE3","title":"Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-06-15","conditions":"Breast Cancer, Adjuvant Therapy","enrollment":1244},{"nctId":"NCT06996093","phase":"PHASE3","title":"Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-06-02","conditions":"Breast Cancer","enrollment":2508},{"nctId":"NCT01783145","phase":"","title":"Shared Care Follow-up After Chemotherapy for Testicular Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2012-10","conditions":"Testicular Cancer","enrollment":163},{"nctId":"NCT05923268","phase":"NA","title":"Molecular Imaging of HER2 Expression in Breast Cancer Using [99mTc]Tc-G3-(G3S)3C Before Chemo/Targeted Therapy","status":"COMPLETED","sponsor":"Tomsk National Research Medical Center of the Russian Academy of Sciences","startDate":"2023-06-04","conditions":"Breast Cancer Female","enrollment":10},{"nctId":"NCT06762665","phase":"NA","title":"RAdiology Consultation Effectiveness","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2025-02-12","conditions":"Radiology Interventional, Spinal Injections, Back Pain","enrollment":270},{"nctId":"NCT06776276","phase":"NA","title":"A Prospective Study: Tai-chi and Post-COVID Insomnia","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2020-09-20","conditions":"Insomnia, COVID - 19","enrollment":337},{"nctId":"NCT06752135","phase":"","title":"Node Positive Cervical Cancer Treated by Neoadjuvant Chemotherapy Plus Radical Surgery: a Single Center Experience","status":"TERMINATED","sponsor":"Azienda Policlinico Umberto I","startDate":"2024-04-10","conditions":"Cervical Carcinoma","enrollment":97},{"nctId":"NCT06669013","phase":"PHASE3","title":"Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas","status":"RECRUITING","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2021-05-20","conditions":"Bone Sarcoma, Embryonal Rhabdomyosarcoma, Alveolar Rhabdomyosarcoma","enrollment":40},{"nctId":"NCT04187898","phase":"PHASE1","title":"Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer","status":"COMPLETED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2020-03-11","conditions":"Neutropenia, Breast Cancer","enrollment":59},{"nctId":"NCT02348489","phase":"PHASE3","title":"SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2015-03-19","conditions":"Leukemia, Myeloid, Acute","enrollment":815},{"nctId":"NCT05236387","phase":"","title":"Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2022-03-01","conditions":"Breast Cancer","enrollment":14},{"nctId":"NCT06154109","phase":"PHASE2","title":"Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Zhiyu Wang","startDate":"2023-11-25","conditions":"Triple Negative Breast Neoplasms","enrollment":90},{"nctId":"NCT03926091","phase":"PHASE3","title":"Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-04-01","conditions":"Breast Cancer","enrollment":2172},{"nctId":"NCT05378087","phase":"NA","title":"Comparing the Efficacy of Surgery Staging and Image Staging of Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2022-06-27","conditions":"Locally Advanced Cervical Cancer","enrollment":1956},{"nctId":"NCT03919552","phase":"PHASE3","title":"Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-01-31","conditions":"Cisplatin, Carboplatin, NPC","enrollment":482},{"nctId":"NCT04180033","phase":"NA","title":"Diagnostic Yield of Colonoscopy Surveillance in Testicular Cancer Survivors Treated With Platinum-based Chemotherapy","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2020-02-18","conditions":"Testicular Cancer, Colorectal Neoplasms","enrollment":154},{"nctId":"NCT05680194","phase":"","title":"Prospective Research for Elderly (≥65 Years Old) Early Breast Cancer Patients","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2022-04-01","conditions":"Breast Cancer Female","enrollment":1000},{"nctId":"NCT02549677","phase":"PHASE4","title":"Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2015-10","conditions":"Breast Neoplasms","enrollment":294},{"nctId":"NCT03705429","phase":"PHASE3","title":"A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2019-05-01","conditions":"Breast Neoplasms","enrollment":51},{"nctId":"NCT05489848","phase":"PHASE2, PHASE3","title":"Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2022-08-20","conditions":"Endometrial Cancer","enrollment":294},{"nctId":"NCT05345860","phase":"NA","title":"Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-03-24","conditions":"Early-stage Breast Cancer","enrollment":300},{"nctId":"NCT01724866","phase":"PHASE2","title":"Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer","status":"COMPLETED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2013-03-25","conditions":"Neutropenia","enrollment":148},{"nctId":"NCT01547741","phase":"PHASE3","title":"Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer","status":"UNKNOWN","sponsor":"NSABP Foundation Inc","startDate":"2012-04","conditions":"Breast Cancer","enrollment":1871},{"nctId":"NCT05302336","phase":"PHASE4","title":"AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-05-01","conditions":"Breast Cancer, Chemotherapeutic Toxicity","enrollment":402},{"nctId":"NCT02953340","phase":"PHASE3","title":"SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide","status":"COMPLETED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2017-05-10","conditions":"Neutropenia, Breast Cancer","enrollment":237},{"nctId":"NCT02643420","phase":"PHASE3","title":"SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)","status":"COMPLETED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2016-01-19","conditions":"Neutropenia, Breast Cancer","enrollment":406},{"nctId":"NCT05131893","phase":"","title":"Neoadjuvant Treatment of Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Oncology, Hungary","startDate":"2022-03","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT04367909","phase":"PHASE2","title":"A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Xin-Hua Xu","startDate":"2020-06-21","conditions":"Oral Squamous Cell Carcinoma","enrollment":68},{"nctId":"NCT00003338","phase":"PHASE2, PHASE3","title":"Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Gilead Sciences","startDate":"1997-03","conditions":"Lymphoma","enrollment":60},{"nctId":"NCT03728829","phase":"","title":"Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast Cancer","status":"UNKNOWN","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2021-07","conditions":"Observational, Prospective","enrollment":100},{"nctId":"NCT00542191","phase":"PHASE2","title":"Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer","status":"TERMINATED","sponsor":"Leo W. Jenkins Cancer Center","startDate":"2007-07","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT00911508","phase":"NA","title":"Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2009-11-13","conditions":"Atrial Fibrillation, Arrhythmia","enrollment":2204},{"nctId":"NCT04536324","phase":"","title":"The Absorption Rate of Subcutaneous Infused Fluid","status":"COMPLETED","sponsor":"Aalborg University Hospital","startDate":"2020-09-01","conditions":"Aged, 75 and Over, Aged, Hypodermoclysis","enrollment":6},{"nctId":"NCT03135951","phase":"PHASE1","title":"Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy","status":"COMPLETED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2017-05-11","conditions":"Breast Cancer, Pharmacokinetics","enrollment":26},{"nctId":"NCT02502864","phase":"PHASE4","title":"Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2016-02-09","conditions":"Breast Cancer, Breast Cancer Female","enrollment":9},{"nctId":"NCT04471480","phase":"NA","title":"TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer","status":"UNKNOWN","sponsor":"Dong Wang","startDate":"2020-09-01","conditions":"ESCC","enrollment":90},{"nctId":"NCT04453904","phase":"NA","title":"Modality of Adjuvant Radiotherapy and Chemotherapy for Stage Ⅲ Endometrial Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2020-05-12","conditions":"Endometrial Cancer","enrollment":654},{"nctId":"NCT02816112","phase":"PHASE4","title":"Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2016-09","conditions":"Early Stage Breast Cancer","enrollment":458},{"nctId":"NCT04280185","phase":"NA","title":"HIPEC in the Treatment of Stage IIc-IV Epithelial Ovarian Cancer After CRS (HIPECOC)","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-06-01","conditions":"Ovarian Cancer, Hyperthermic Intraperitoneal Chemotherapy","enrollment":202},{"nctId":"NCT04127019","phase":"PHASE3","title":"Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)","status":"COMPLETED","sponsor":"Fudan University","startDate":"2010-06-01","conditions":"Primary Breast Cancer","enrollment":2079},{"nctId":"NCT01671319","phase":"PHASE2","title":"Dose Dense TC + Pegfilgrastim Support for Breast Cancer","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2011-06","conditions":"Female Breast Cancer","enrollment":42},{"nctId":"NCT01104935","phase":"PHASE3","title":"National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT]","status":"COMPLETED","sponsor":"Comprehensive Support Project for Oncology Research","startDate":"2009-10-28","conditions":"Breast Cancer","enrollment":275},{"nctId":"NCT00911716","phase":"NA","title":"TC Avastin. ICORG 08-10, V6","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2008-10","conditions":"Breast Cancer","enrollment":106},{"nctId":"NCT02457039","phase":"NA","title":"Acupuncture Prevents Chemobrain in Breast Cancer Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2015-10","conditions":"Chemo-brain, Drug-Related Side Effects and Adverse Reactions, Mild Cognitive Impairment","enrollment":93},{"nctId":"NCT01867229","phase":"","title":"Breast Cancer and Chemo-amennorhea","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2011-10","conditions":"Breast Cancer","enrollment":7},{"nctId":"NCT01723163","phase":"NA","title":"Abstinence Reinforcement Therapy (ART) for Rural Veteran Smokers","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2013-11-21","conditions":"Veteran, Smoking Cessation","enrollment":310},{"nctId":"NCT00681993","phase":"NA","title":"Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-04","conditions":"Breast Cancer","enrollment":35},{"nctId":"NCT02737709","phase":"PHASE2","title":"Paclitaxel Detection in NSCLC Treated With TC Regimen","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2016-03","conditions":"Non-small Cell Lung Cancer","enrollment":51},{"nctId":"NCT01648322","phase":"PHASE2","title":"Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","status":"COMPLETED","sponsor":"EVIVE Biotechnology","startDate":"2012-06","conditions":"Breast Cancer, Neutropenia","enrollment":232},{"nctId":"NCT03636685","phase":"PHASE1, PHASE2","title":"Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2018-08-15","conditions":"NSCLC, Adenocarcinoma, Squamous Cell Carcinoma","enrollment":60},{"nctId":"NCT01501487","phase":"PHASE4","title":"MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I","status":"COMPLETED","sponsor":"Agendia","startDate":"2011-10","conditions":"Breast Cancer","enrollment":226},{"nctId":"NCT00256243","phase":"PHASE2","title":"Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer","status":"COMPLETED","sponsor":"Rita Sanghvi, Mehta","startDate":"2004-04","conditions":"Breast Cancer","enrollment":48},{"nctId":"NCT03366883","phase":"PHASE3","title":"Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2018-02-01","conditions":"Esophageal Cancer Stage IIB, Esophageal Cancer Stage III","enrollment":420},{"nctId":"NCT03373708","phase":"PHASE2, PHASE3","title":"Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer","status":"UNKNOWN","sponsor":"Zhiyong Yu","startDate":"2017-12-20","conditions":"Breast Cancer, Chemotherapy, Endocrine Breast Diseases","enrollment":200},{"nctId":"NCT03349177","phase":"PHASE2, PHASE3","title":"Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Zhiyong Yu","startDate":"2017-11-27","conditions":"Breast Cancer, Pathological Complete Response, Neoadjuvant Chemotherapy","enrollment":200},{"nctId":"NCT02483767","phase":"PHASE3","title":"Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2015-06","conditions":"Breast Cancer","enrollment":98},{"nctId":"NCT03175848","phase":"NA","title":"Chemotherapy Plus Radiation Therapy in Treating Patients With Primary Stage IVB Cervical Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2017-05-05","conditions":"Cervical Cancer Stage IVB","enrollment":48},{"nctId":"NCT00912444","phase":"PHASE3","title":"Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer","status":"TERMINATED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2009-07","conditions":"Breast Cancer","enrollment":102},{"nctId":"NCT02969278","phase":"NA","title":"Groin Sentinel Node Biopsy and 18FDG-PET/CT in cN0 Vulvar Cancer Patients Candidate to Standard Lymphadenectomy","status":"UNKNOWN","sponsor":"Catholic University of the Sacred Heart","startDate":"2013-07","conditions":"Vulvar Cancer","enrollment":50},{"nctId":"NCT02934828","phase":"PHASE2","title":"Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2014-10","conditions":"Breast Cancer","enrollment":230},{"nctId":"NCT00295789","phase":"PHASE3","title":"Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)","status":"COMPLETED","sponsor":"Haruhiko Fukuda","startDate":"2006-02","conditions":"Uterine Cervical Neoplasms","enrollment":253},{"nctId":"NCT00636441","phase":"PHASE2","title":"Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer","status":"TERMINATED","sponsor":"Duke University","startDate":"2008-04","conditions":"Early-Stage Breast Cancer","enrollment":56},{"nctId":"NCT01891123","phase":"NA","title":"Explore the Individual Treatment of Docetaxel and Paclitaxel in NSCLC, NPC and BRC by PK-guided Dosing Strategy","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2013-06","conditions":"Non-small Cell Lung Cancer, Breast Cancer, Nasal Cancer","enrollment":300},{"nctId":"NCT02464774","phase":"NA","title":"Breast-Conserving Therapy in Patients With Triple-Negative Breast Cancer","status":"UNKNOWN","sponsor":"Xiaoming Xie","startDate":"2015-07","conditions":"Breast Cancer","enrollment":464},{"nctId":"NCT01123967","phase":"NA","title":"Offering Proactive Tobacco Treatment","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2011-02","conditions":"Tobacco Use Cessation","enrollment":2500},{"nctId":"NCT02249208","phase":"PHASE3","title":"Sentinel Lymph Node Biopsy With Superparamagnetic Iron Oxide for Breast Cancer Patients After Neoadjuvant Treatment.","status":"UNKNOWN","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2014-04","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT00052468","phase":"PHASE3","title":"Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"AGO Study Group","startDate":"2002-08","conditions":"Fallopian Tube Cancer, Ovarian Cancer","enrollment":1742},{"nctId":"NCT01985724","phase":"PHASE3","title":"Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","startDate":"2007-10","conditions":"Breast Cancer","enrollment":650},{"nctId":"NCT01301040","phase":"PHASE2","title":"Early Cardiac Toxicity of Adjuvant CT in Elderly BC.","status":"TERMINATED","sponsor":"Jules Bordet Institute","startDate":"2011-03","conditions":"Breast Cancer","enrollment":2},{"nctId":"NCT01917578","phase":"PHASE3","title":"Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2008-08","conditions":"Breast Cancer","enrollment":4},{"nctId":"NCT01838538","phase":"PHASE2","title":"Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2011-06","conditions":"Ovarian Cancer With Malignant Ascites","enrollment":54},{"nctId":"NCT01099124","phase":"NA","title":"Study of M2ES With Paclitaxel/Carboplatin (TC Regimen) in Advanced Non Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2009-12","conditions":"Non Small Cell Lung Cancer","enrollment":25},{"nctId":"NCT00578617","phase":"NA","title":"Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2006-09","conditions":"Atrial Fibrillation, Arrhythmia","enrollment":60},{"nctId":"NCT00004873","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Advanced Stomach Cancer","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"1999-08","conditions":"Gastric Cancer","enrollment":""},{"nctId":"NCT00080860","phase":"NA","title":"Sentinel Lymph Node Biopsy and Primary Tumor Gene Expression Profiling in Finding Axillary Lymph Node Metastases in Women Who Have Received Neoadjuvant Therapy for Stage II, Stage III, or Stage IV Breast Cancer","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2004-02","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT01526499","phase":"PHASE2","title":"Docetaxel With or Without Metronomic Cyclophosphamide as First Line Chemotherapy in Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2011-12","conditions":"Breast Cancer","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":55,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"TC chemotherapy","genericName":"TC chemotherapy","companyName":"Agendia","companyId":"agendia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TC chemotherapy, which consists of a combination of drugs including Docetaxel and Cyclophosphamide, is used to treat various conditions such as breast cancer, HER 2 Negative Breast Cancer, and Acute Myeloid Leukemia. TC chemotherapy is a small molecule modality, classified as a type of chemotherapy treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}